# US 2017/0253635 A1 · Antifungal agents and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0253635 A1
- Document ID: US20170253635A1
- Status: Published application
- Kind: A1
- Application number: 15/598,913
- Filed: 2017-05-18
- Published: 2017-09-07
- Earliest claimed: 2011-03-03
- Assignees: Cidara Therapeutics, Inc.
- Applicants: Cidara Therapeutics, Inc.
- Inventors: Kenneth Duke JAMES, JR.; Christopher Patrick LAUDEMAN; Navdeep Balkrishna MALKAR; Balasingam RADHAKRISHNAN
- Web page: https://patentgrep.com/patent/US20170253635A1

## CPC

- C07K 7/64: Cyclic peptides containing only normal peptide links
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/02: Nasal agents, e.g. decongestants
- A61P 13/02: of urine or of the urinary tract, e.g. urine acidifiers
- A61P 15/02: for disorders of the vagina
- A61P 17/00: Drugs for dermatological disorders
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/10: Antimycotics
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 7/00: Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K 7/56: the cyclisation not occurring through 2,4-diamino-butanoic acid
- C07K 7/60: the cyclisation occurring through the 4-amino group of 2,4-diamino-butanoic acid
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 38/04: Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof ({enzyme inhibitors A61K38/005;} gastrins {A61K38/2207}, somatostatins A61K38/31, melanotropins A61K38/34 {; protease inhibitors A61K38/55})
- A61K 38/08: Peptides having 5 to 11 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61K 38/12: Cyclic peptides {, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C (A61K38/043 - A61K38/046 take precedence)}
- C07K 7/50: Cyclic peptides containing at least one abnormal peptide link
- C07K 7/54: with at least one abnormal peptide link in the ring
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The invention features echinocandin class compounds. The compounds can be useful for the treatment of fungal infections.

## Claims

### Claim 1

A compound having the formula:
or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The compound of claim 1, wherein said compound is an acetate salt.

### Claim 3 (depends on 1)

The compound of claim 1, wherein said compound is a chloride salt.

### Claim 4 (depends on 1)

A pharmaceutical composition comprising the compound of claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

### Claim 5 (depends on 4)

The pharmaceutical composition of claim 4, wherein said compound is an acetate salt.

### Claim 6 (depends on 4)

The pharmaceutical composition of claim 4, wherein said compound is a chloride salt.

### Claim 7 (depends on 4)

The pharmaceutical composition of claim 4, wherein said pharmaceutical composition is formulated for oral administration.

### Claim 8 (depends on 4)

The pharmaceutical composition of claim 4, wherein said pharmaceutical composition is formulated for intravenous administration.

### Claim 9 (depends on 4)

The pharmaceutical composition of claim 4, wherein said pharmaceutical composition is formulated for topical administration.

### Claim 10 (depends on 4)

The pharmaceutical composition of claim 4, wherein said pharmaceutical composition is formulated for subcutaneous administration.

### Claim 11 (depends on 4)

The pharmaceutical composition of claim 4, wherein said pharmaceutical composition is formulated for inhalation.

### Claim 12 (depends on 4)

A method of treating a fungal infection in a subject, said method comprising administering to said subject a pharmaceutical composition of claim 4 in an amount sufficient to treat said infection.

### Claim 13 (depends on 12)

The method of claim 12, wherein said pharmaceutical composition is administered orally.

### Claim 14 (depends on 12)

The method of claim 12, wherein said pharmaceutical composition is administered intravenously.

### Claim 15 (depends on 12)

The method of claim 12, wherein said pharmaceutical composition is administered topically.

### Claim 16 (depends on 12)

The method of claim 12, wherein said pharmaceutical composition is administered subcutaneously.

### Claim 17 (depends on 12)

The method of claim 12, wherein said pharmaceutical composition is administered by inhalation.

### Claim 18 (depends on 12)

The method of claim 12, wherein said pharmaceutical composition is administered to treat a blood stream infection or tissue infection in said subject.

### Claim 19 (depends on 12)

The method of claim 12, wherein said infection is selected from tinea capitis, tinea corporis, tinea pedis, onychomycosis, perionychomycosis, pityriasis versicolor, oral thrush, vaginal candidosis, respiratory tract candidosis, biliary candidosis, eosophageal candidosi, urinary tract candidosis, systemic candidosis, mucocutaneous candidosis, aspergillosis, mucormycosis, paracoccidioidomycosis, North American blastomycosis, histoplasmosis, coccidioidomycosis, sporotrichosis, fungal sinusitis, or chronic sinusitis.

### Claim 20 (depends on 12)

The method of claim 12, wherein wherein said fungal infection is an infection of Candida albicans, C. parapsilosis, C. glabrata, C. guilliermondii, C. krusei, C. tropicalis, C. lusitaniae, Aspergillus fianigatus, A. flams, A. terretis, A. niger, A. Candidas, A. clavatus, or A. ochraceus.

### Claim 21 (depends on 3)

A method of preventing a fungal infection in a subject, said method comprising administering to said subject a pharmaceutical composition of claim 3 in an amount sufficient to prevent said infection.

### Claim 22 (depends on 21)

The method of claim 21, wherein said pharmaceutical composition is administered intravenously.

### Claim 23 (depends on 22)

The method of claim 22, wherein said subject is being prepared for an invasive medical procedure, said subject is immunocompromised, or said subject is undergoing long term antibiotic therapy.

### Claim 24 (depends on 1)

A method of preventing, stabilizing, or inhibiting the growth of fungi, or killing fungi, said method comprising contacting said fungi or a site susceptible to fungal growth with a compound of claim 1.
